Although both the disease and the treatment for it in rheumatology patients may work at cross-purposes with immunizations, only a very few vaccines are absolutely contraindicated in this population, an infectious disease specialist told rheumatologists here.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.
An NIH funded prospective study has shown that the use of daily dietary supplements was not associated with a subsequent lowering of mortality risk.
A study from UT Southwestern and the Baylor Research Institute examined the preceptions and practices of women with autoimmune or inflammatory rheumatic diseases (AIRD) noting that an AIRD diagnosis changed most womens future hopes and plans regarding pregnancy and lactation.
The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.
A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.
“If you don't know what you want, you end up with a lot you don't.” ― Chuck Palahniuk, "Fight Club" 1999
I have been a clinical investigator for 16 years, engaged in phase I to IV company-sponsored trials as well as NIH and investigator initiated studies. There are certain rules - written and unwritten - for participating in research as an investigator.
The American College of Rheumatology Committee on Rheumatologic Care has released new drug pricing and step therapy position statements that they hope legislators will consider as they continue to explore policy and regulatory options to make drugs more affordable and accessible.
Interstitial lung disease (ILD) has been a hot topic in numerous journals recently with reports of increasing incidence and links to disease activity.
A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.
A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.
A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.
A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.
A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.
